Nuvation Bio Inc (NYSE:NUVB) has a beta value of 1.44 and has seen 4.52 million shares traded in the last trading session. The company, currently valued at $775.57M, closed the last trade at $2.29 per share which meant it gained $0.41 on the day or 21.81% during that session. The NUVB stock price is -81.66% off its 52-week high price of $4.16 and 27.07% above the 52-week low of $1.67.
The consensus among analysts is that Nuvation Bio Inc (NUVB) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.12.
Nuvation Bio Inc (NYSE:NUVB) trade information
Sporting 21.81% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NUVB stock price touched $2.29 or saw a rise of 2.55%. Year-to-date, Nuvation Bio Inc shares have moved -13.91%, while the 5-day performance has seen it change 25.82%. Over the past 30 days, the shares of Nuvation Bio Inc (NYSE:NUVB) have changed -3.78%.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 67.29% from current levels. The projected low price target is $7.0 while the price target rests at a high of $7.0. In that case, then, we find that the current price level is -205.68% off the targeted high while a plunge would see the stock gain -205.68% from current levels.
Nuvation Bio Inc (NUVB) estimates and forecasts
The company’s shares have lost -17.92% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 60.39%.
3 analysts offering their estimates for the company have set an average revenue estimate of 833.33k for the current quarter. 3 have an estimated revenue figure of 833.33k for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -49.14% over the past 5 years. Earnings growth for 2025 is a modest 73.12% while over the next 5 years, the company’s earnings are expected to increase by 35.86%.
NUVB Dividends
Nuvation Bio Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
The top two institutional holders are FMR LLC with over 28.82 million shares worth more than $84.16 million. As of 2024-06-30, FMR LLC held 13.1578% of shares outstanding.
The other major institutional holder is ECOR1 CAPITAL, LLC, with the holding of over 19.21 million shares as of 2024-06-30. The firm’s total holdings are worth over $56.09 million and represent 7.8491% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 4.10% shares in the company for having 13.83 shares of worth $31.67 million while later fund manager owns 8.96 shares of worth $20.51 million as of Dec 31, 2024 , which makes it owner of about 2.65% of company’s outstanding stock.
